Allergan sues Watson over US Sanctura XR patent
This article was originally published in Scrip
Executive Summary
Allergan has filed suit in the US District Court for the District of Delaware against Watson Laboratories, alleging patent infringement related to its generic version of the overactive bladder treatment Sanctura XR (trospium chloride extended-release capsules), thus triggering paragraph IV litigation and the 30-month stay of approval while the legal challenge is fought.